Statistical Significance Achieved Compared to Conventional Injection Method

GC Green Cross Wellbeing announced on June 16 that it has secured topline results showing that its high-dose intravenous (IV) infusion method of Linek Injection, currently under development as a treatment for chronic liver disease, met its primary endpoint in a Phase 3 clinical trial.


In this Phase 3 clinical trial, conducted from April 2024 at 18 institutions in Korea and involving 226 patients with chronic liver disease, the company compared the efficacy and safety of high-dose intravenous infusion of Linek Injection with subcutaneous administration. The clinical results showed that the intravenous infusion group demonstrated a statistically significant difference (p=0.0098) compared to the subcutaneous group in the change of alanine aminotransferase (ALT) levels from baseline at 6 weeks, which was the primary endpoint.


GC Green Cross Wellbeing Linek. GC Green Cross Wellbeing

GC Green Cross Wellbeing Linek. GC Green Cross Wellbeing

View original image

GC Green Cross Wellbeing stated that, based on these topline results, it plans to submit an application for a label change to the Ministry of Food and Drug Safety after receiving the final clinical study report (CSR). Since its launch in 2005, Linek Injection is expected to surpass 100 million cumulative doses sold by 2026, and with this expanded indication, the company anticipates over KRW 20 billion in additional annual sales.



Ji Young Jung, Head of Research and Development at GC Green Cross Wellbeing, said, "Based on the data secured, we plan to promptly apply for product approval from the Ministry of Food and Drug Safety within this year, and we expect to provide patients with a more effective and safer treatment option in the future."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing